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ABSTRACT
To better understand the complex role that alter-
native splicing plays in intracellular signaling,
it is important to catalog the numerous splice
variants involved in signal transduction. Therefore,
we developed PASE (Prediction of Alternative
Signaling Exons), a computational tool to identify
novel alternative cassette exons that code for
kinase phosphorylation or signaling protein-binding
sites. We first applied PASE to the Caenorhabditis
elegans genome. In this organism, our algorithm
had an overall specificity of  76.4%, including
33 novel cassette exons that we experimentally
verified. We then used PASE to analyze the human
genome and made 804 predictions, of which 308
were found as alternative exons in the transcript
database. We experimentally tested 384 of the
remaining unobserved predictions and discovered
26 novel human exons for a total specificity of
 41.5% in human. By using a test set of known
alternatively spliced signaling exons, we determined
that the sensitivity of PASE is  70%. GO term
analysis revealed that our exon predictions were
found in the introns of known signal transduction
genes more often than expected by chance, indicat-
ing PASE enriches for splice variants that function in
signaling pathways. Overall, PASE was able to
uncover 59 novel alternative cassette exons in C.
elegans and humans through a genome-wide ab
initio prediction method that enriches for exons
involved in signaling.
INTRODUCTION
One intriguing aspect of signal transduction is that
there seems to be a relatively small number of signaling
pathways, yet cells are able to generate multiple
responses to diﬀerent signals from the environment.
One explanation is that alternative splicing of
pre-mRNA generates a much larger number of unique
signaling proteins than is generally appreciated, thus
enabling a diverse set of responses. Several pieces of
evidence support this hypothesis. Bioinformatics analysis
and DNA microarray experiments indicate that 59–74%
of all human genes are alternative spliced (1,2) and that
roughly 75% of alternative splicing events alter the
protein-coding region of the transcript (3–5). This
suggests that alternative splicing has the potential to
produce a large number of diﬀerent proteins from the
surprisingly limited number of genes in multicellular
organisms. The connection between alternative splicing
and intracellular signaling is further strengthened by
studies of glucocorticoid signaling, where it has been
shown that alternative splicing is the mechanism by which
a single gene (the glucocorticoid receptor) is able to
mediate a variety of diﬀerent responses in diﬀerent cell
types (6). Similar results have been observed in other
signaling pathways—both the g-amino-butyric acid type
A receptor gamma-subunit (GABAAR g2) gene and
the myosin light chain kinase (MLCK) gene contain
alternative cassette exons that encode for phosphorylation
sites that alter their signaling functions (7–9).
In order to accelerate our eﬀorts to understand the
role alternative splicing plays in intracellular signaling
pathways, we need to identify and accurately catalog
alternatively spliced (AS) isoforms involved in signal
transduction. However, there are currently several
diﬃculties to obtaining such a catalog. While most
known alternative-splicing events have been discovered
through large-scale EST sequencing, this approach
has some drawbacks. First, in many model organisms,
where intracellular signaling is most easily dissected,
relatively few EST sequences have been collected
(e.g. Caenorhabditis elegans  300000 ESTs). Even in
organisms with high EST coverage such as human, many
AS isoforms go undetected because EST libraries are
biased to highly expressed splice forms as well as to the
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not captured by this conventional approach because of
their speciﬁc expression in particular tissues or develop-
mental stages. Indeed, many human tissues have not been
adequately sampled—there are  210 human cell types (10)
and many of these have little or no EST coverage. Finally,
even when AS transcripts are found, their functions are
often unknown. As a result, our ability to detect alternative
splice variants and determine their function is limited.
Recognitionoftheseshortcomingshassparkedconsider-
able interest in developing computational approaches to
splice variant prediction (11). Attempts at ab initio
prediction of alternative splicing that is based on intronic
sequence alone have proven diﬃcult because of the high
number of pseudo-splice sites in intronic sequences (12).
In addition, many of the known AS cassette exons that
aﬀect signaling are quite small, and may be diﬃcult to ﬁnd
by conventional gene prediction methods alone. Recently,
progresshasbeenmadeusingspeciesconservationaswellas
protein domain information (13–15), yet the total number
of experimentally validated novel isoforms remains modest
compared to the numbers found by traditional EST
sequencing. Also, no hypothesis can be made about the
function of these observed alternative splice variants.
To complement these approaches and to address the
issue of ﬁnding signaling exons, we developed prediction
of alternative signaling exons (PASE), a computational
tool to identify AS cassette exons that are likely to be
involved in intracellular signaling. This algorithm uses
ﬁrst-order Markov models and a Bayesian classiﬁer to
identify likely donors and acceptor sites in an intron.
Using these potential splice sites, it identiﬁes in-frame
cassette exons that code for phosphorylation sites or
signaling protein-binding sites. As an additional ﬁlter,
only exons that are conserved across species are kept.
Here, we report the results of a genome-wide application
of our algorithm and demonstrate that our genome-wide
ab initio approach enriches for novel exons likely to be
involved in cell signaling.
METHODS
Preparation of intron, EST/mRNA and species
conservation data
All intron data sets were processed from REFSEQ
genomic alignment annotations, which were downloaded
from the UCSC Genome Browser (May 2004 release).
Redundant transcripts and intron-less genes were removed
from both human and C. elegans data sets. Spliced-ESTs
and phastCons ‘Most conserved’ species conservation
blocks were downloaded as chromosome coordinate data
from the UCSC Genome Browser (as of January 2, 2005).
Two PERL programs (compare_to_expressedseq.pl
and compare_to_conserved.pl) were written to compare
the overlap of coordinates from these data sets to the
predicted exon coordinate data.
Acceptor and donorsplice site scoring
The C. elegans and human cassette exon models consist
of the pairing of acceptor and donor splice sites with an
exon size restriction of 30–330bp. Both acceptor and
donor splice site models use 12-mer ﬁrst-order Markov
chains to capture the over-represented dinucleotide
frequencies around the splice sites (34). These models
were trained on a randomly sampled set of 5000 REFSEQ
internal exons from human and C. elegans genome,
respectively.
Calculation of the ﬁrst-order Markov chain model of
the splice site:
Pðsplice siteÞ¼Px 1 ðÞ P &
12
i¼2
 Px i xi 1 j ðÞ :
Log-odds ratio of the splice site versus the background
probability Pb:
log2
Pðsplice siteÞ
Pb
  
:
The background probabilities were calculated by
counting the overlapping dinucleotide frequencies of all
intronic sequences from the REFSEQ genes of each
genome.
Bayesianclassificationofanacceptor–donorpairexonmodel
A Bayesian classiﬁer was trained and tested with sets of
real and pseudo-exon acceptor–donor pair scores. Pseudo-
exons in this case are any pair of AG–GT dinucleotides
within range of the exon size limits taken from randomly
generated intronic sequences based on species-speciﬁc
dinucleotide distribution. For the human test set, a ratio
of 1:10 real exons to pseudo-exons was used (1000 real
exons versus 10000 pseudo-exons), reﬂecting the order of
magnitude number of pseudo-exons relative to real exons
typically found in the human genome (12). The C. elegans
test set had a 1:4 ratio (1000 real exons versus 4000
pseudo-exons) of real exons to pseudo-exons. Training of
the Bayesian classiﬁer parameters for both the real and
pseudo-exon acceptor–donor pair score distributions were
calculated by using multivariate Gaussian distributions
with the prior probabilities based on the ratios of real
exon to pseudo-exons.
The function for the Multivariate Gaussian distribution
model for exon acceptor–donor pair scores is the following:
Let xi¼{acceptor bit score, donor bit score},
  ¼covariance matrix of acceptor and donor bit score
distributions and det ( )¼determinant of the covariance
matrix
f ¼
1
2 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
detð Þ
p e2ðxi  xÞ  1ðxi  xÞ
T
:
The calculation of the probability that an exon is real,
given its acceptor–donor pair scores is the following:
Let P(R) and P(P) be the prior probability of Real
Exons and Pseudo-Exons, respectively
P Real xi j ðÞ ¼
freal   PðRÞ
½freal   PðRÞþfpseudo   PðPÞ 
:
Exon translations
A PERL program (intron_phase.pl) was written to
determine the reading frames of exons and the phase
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was spliced. When predicting exons, we also translated the
ﬁve ﬂanking amino acids from both of the adjacent
constitutive exons (See Supplementary Data).
PASE-sensitivity test
A splicing events data ﬁle ‘AltSplice-rel3.events.txt’ and
gene sequence ﬁle ‘AltSplice-rel3.genes.txt.gz’ were
downloaded from Alternative Splicing Database (http://
http://www.ebi.ac.uk/asd/) (24). Single cassette exon
splicing events and their sequences were extracted using
‘get_single_cassette.pl’ PERL program. WU-BLAST was
used for BLASTX comparison with the Phospho.ELM
database (25) and only exons with 100% identity were
selected. PASE was then applied to corresponding
REFSEQ gene structures that lack the cassette exons.
Creationof Scansite log-oddsmatrices
The current release of Scansite (version 2.0) includes
63 motifs characterizing the binding and/or substrate
speciﬁcities of many families of Ser/Thr- or Tyr-kinases,
SH2, SH3, PDZ, 14-3-3 and PTB domains, together with
signature motifs for PtdIns(3,4,5)P3-speciﬁc PH domains
(35). PDZ-binding motifs were excluded due to the
COOH-terminal sequence requirement. We modiﬁed
the Scansite matrices to be log-odds scoring matrices
to take into account the background distribution of the
proteomes for human and C. elegans. This modiﬁcation
allowed us to compare the information content of the
matrices (Supplementary Table A) and to rank the scores
of predicted functional exons independent from percentile
ranking (See Supplementary Data).
Let Sij be the Scansite selectivity value of amino acid i in
position j:
PA ij PSSM j
  
¼
Sij P
Sj
:
The calculation of the log-odds scoring matrix is the
following:
Mij ¼ log2ðPðAijjPSSMÞ=PðAijBackgroundÞÞ:
Using these matrices, a PERL script was written
(ﬁnd_scansite.pl) to search the putative exons for signaling
motifs using bit score thresholds of 10 and 6 bits.
Primerdesign of selected candidates
Batch processing of the primer design for all candidate
exons was done with a PERL program (prediction_to_
primer3.pl) in combination with the PRIMER3 soft-
ware (36). Primers were designed using the following
PRIMER3 settings: primer length minimum, 19nt,
desired; 25nt and maximum, 32nt; melting temperature
minimum, 648C, desired length, 708C and maximum
length, 738C; minimum GC content of 45, and maximum
of 80; product length, 150–700nt; and pre-ﬁltering of
potentially mispriming sequences with the provided
library of human repeats. Figure 3 illustrates the primer
design and the expected PCR products. Primer sequences
were ordered from Integrated DNA Technologies,
Coralville, IN, USA (list of primers available in
Supplementary Data).
Semi-nested RT-PCR experiments
Pooled total RNA samples from 18 diﬀerent tissues types
were used for semi-nested PCR validation in human
(Supplementary Table D). Total RNA from whole worms
were used for PCR validation in C. elegans. Superscript II
Reverse Transcription (Invitrogen, Carlsbad, CA, USA)
was used to create cDNA with candidate gene-speciﬁc
reverse primers. All cDNA samples were tested for the
presence of RNA Polymerase II transcript as a control.
The cDNA from all tissues was then pooled together and a
1:10 dilution was made to be used as a template for the
ﬁrst round of semi-nested PCR. PCR was carried out with
the Sigma Jumpstart Taq DNA polymerase kit on an MJ
Research PTC-200 (Bio-Rad Laboratories, Mississauga,
ON, Canada), with ﬁrst round of 25 cycles (45s at 948C),
annealing (30s at 568C) and extension (1min at 728C)
and second round for 35 cycles using the same program
using 1:100 dilution of ﬁrst round reaction as template.
PCR products were separated in 2% agarose gels
supplemented with ethidium bromide, under a UV light.
High-throughput analysis using Phoretix 1D (Nonlinear
Dynamics, Newcastle upon Tyne, UK) facilitated multiple
lane band size determinations for all PCR experiments.
Cloning and sequencing
Second round PCR products of the expected predicted
size were then ligated into pGEM-T Easy TA cloning
vectors (Promega, Madison, WI, USA) and transformed
into GeneChoice High Eﬃciency GC10 chemically
competent cells (Cat No. D-1). Bacterial clones were
plated on LB/X-gal/IPTG agar plates and grown
overnight at 378C. A maximum of 24 colonies were
picked from each plated transformation and used for
colony PCR with standard M13 primers. Two microliters
of this colony PCR product was then used as the template
for cycle sequencing using Applied Biotech, Inc. BigDye
Terminator v3.1 Cycle Sequencing Kit (cat no. 4336917)
and then run on an ABI 3700.
GO term over-representation
The gene ontology (GO) terms were taken from the
non-redundant ermineDB GO database (37). In this
database, 3080 genes are annotated with the signal
transduction GO term ID 0007165 out of a total 18506
annotated human gene products. Sampling of the genes
was done without replacement, therefore we calculated the
probability of sampling r genes annotated to a given GO
term by using the hypergeometric distribution:
hk,N,M ðrÞ¼
M
r
  
N
k   r
  
N þ M
k
   ,
where k is the number of genes in our study set, M the
total number of genes in the population annotated to the
3194 Nucleic Acids Research, 2007, Vol. 35, No. 10term in question, while N is the total number of genes in
the population not annotated to the GO term. The
probability of seeing r or more annotations in our study
set using the sum over the upper tail of the hypergeometric
distribution is the following:
X k
i¼r
hk,N,M ðiÞ:
Accession numbers
The RT-PCR veriﬁed sequences that were sequenced
were deposited in Genbank, under accession numbers
EF491733–EF491822.
RESULTS
Overview ofPASE
Our goal was to develop an algorithm that would identify
novel alternative cassette exons involved in intracellular
signaling. We focused on single cassette exons because
they make up the signiﬁcant portion (53–61%) of
alternative splicing events in most species (16,17). Our
algorithm can be summarized in the following steps
(Figure 1):
(1) Identify cassette exon splicing events using splice-site
Markov models and a Bayesian classiﬁer.
(2) Translate candidate exons and remove those that
have premature stops or altered reading frames.
(3) Select exons that are in conserved sequence regions
between species.
(4) Select exons with predicted phosphorylation or
protein-binding motifs known to be involved in
intracellular signaling.
We discuss each of these steps below.
Identification of cassette exons. PASE ﬁrst scans intronic
sequences of REFSEQ gene structures for candidate
cassette exons. Candidate cassette exons must have pairs
of acceptor and donor splice sites within 30–330bp of
each other. Splice site models were generated by training
12-position ﬁrst-order Markov chains of over-represented
dinucleotides for both acceptor and donor splice sites
from a randomly sampled training set of real exons
from human REFSEQ and C. elegans WORMBASE
annotations. We then trained a Bayesian classiﬁer to
discriminate acceptor–donor pair scores of real exons
from pseudo-exons of similar length. Pseudo-exons are
any pair of acceptors and donors generated from a
random background intronic sequence distribution.
This classiﬁer achieved an average of 96% accuracy on
multiple training set runs for both C. elegans and human
test sets (See Methods section).
Exon amino acid translations. Alternative exons that
introduce frameshifts or premature stop codons are
under strong negative selection and are not likely to be
functional because they disrupt protein structure (18).
Therefore, PASE ﬁlters out predicted exons with in-frame
stop codons or whose length in base pairs was not a
multiple of three, as these cause frameshifts.
Species conservation of exons. Sequences encoding
alternative exons are signiﬁcantly more conserved than
neutral sequences (19,20). Furthermore, orthologous
exons that are alternative in other species are often
found to be more conserved than orthologous constitutive
exons and they often have conserved intronic sequences
ﬂanking them (14,21). PASE requires predicted exons to
overlap sequences that are identiﬁed as conserved by
the PhastCons phylo-HMM program. This algorithm
identiﬁes blocks of highly conserved genomic sequence
elements using results from multiple sequence alignments
of up to 17 diﬀerent vertebrate species when compared to
human (22). For C. elegans, only C. briggsae was used for
comparative genomics.
Signaling interaction motifs. To ﬁnd cassette exons that
encode for signaling motifs, we modiﬁed the Scansite 2.0
algorithm (http://scansite.mit.edu) (23) and used it to
identify cassette exons with intracellular signaling
motifs. Scansite uses a database of experimentally
generated position-speciﬁc scoring matrices (PSSMs) to
identify signaling motifs such as kinase phosphorylation
sites, SH2 and SH3 domains (Figure 2). We modiﬁed
this algorithm to use an information-content-based
1. Predict single cassette exon splicing events within introns
2. Remove exons with premature stops or frame shifts
3. Select exons within conserved genomic regions between species
4. Select exons containing predicted Scansite signaling motifs
Species A
Species B
Species C
P
intron RefSeq
Constitutive exon 3 Constitutive exon 4
Figure 1. Overview of the PASE algorithm. (1) PASE ﬁrst scans
intronic sequences of RefSeq genes for candidate cassette exons.
(2) Predicted exons that introduce frameshifts or premature stop
codons are removed. (3) Exons that overlap blocks of highly conserved
genomic sequence elements are then selected. (4) Finally, the remaining
cassette exons are searched with Scansite motifs to identify candidate-
signaling exons.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3195scoring system, and to account for the species-speciﬁc
background frequencies of the diﬀerent amino acids.
These modiﬁcations were important for improving motif
score thresholds in our application (see Supplementary
Data). We then scored all putative exons against PSSMs
for 59 cell signaling motifs (Supplementary Table A).
PredictionofalternativelysplicedsignalingexonsinC.elegans
Caenorhabditis elegans is a model organism that is often
used to study signal transduction because it shares many
pathways with human and mouse but is more amenable to
rapid genetic manipulation. Furthermore, relatively few
ESTs have been sequenced from C. elegans (300000 ESTs
sequenced from worm versus  7 10
6 sequenced from
human), so this represents an ideal organism to try an
ab initio approach to ﬁnd novel alternative exons involved
in signaling. Using the C. elegans genome sequence as
input, PASE predicted 140 putative alternative exons
involved in signaling (Table 1). Seventy-four of these
could be identiﬁed in the C. elegans spliced-ESTs database
(Supplementary Table B). The remaining 66 predictions
represent either novel alternative exons or false positives
and were selected for experimental validation.
Experimental validation of novel C. elegans predictions
We pooled C. elegans total RNA from a mixture of
developmental stages. Next we performed semi-nested
RT-PCR speciﬁc to the predicted alternative exons
followed by agarose gel electrophoresis (Figure 3).
Bands of the predicted size were cloned and sequenced
to determine if the predicted exon was present in the
product. We evaluated 66 predictions and found 33 novel
exons with correctly predicted 50 splice junctions (50%, see
Table 2). These results, together with the 74 predictions
already supported by the EST data, indicate the speciﬁcity
[TP/(TPþFP)] of our algorithm is  76.4% (107/140) in
C. elegans.
Figure 2. Examples of Scansite motifs used in PASE. (A) Akt kinase (also known as Protein Kinase B) is a member of the basophilic serine/
threonine-speciﬁc protein kinase family that selectively phosphorylates the serine/threonine residue (position 0) of protein sequences resembling the
linear motif R-X-R-X-X-S/T. (B) The non-catalytic Src Homology 3 (SH3) domain of the tyrosine kinase Src mediates speciﬁc protein–protein
interactions by binding to ligands with the linear motif resembling R-X-X-P-X-X-P.
1st 1st 2nd 2nd Clone and sequence Clone and sequence
1st 1st
2nd 2nd
25 cycles 25 cycles
35 cycles 35 cycles
1:100 1:100
dilution dilution
Predicted
Exon
261bp 261bp
156bp 156bp
   λ
Figure 3. Semi-nested RT-PCR approach to detect novel exons from a
pool of 18 tissue RNA samples. In the ﬁrst round of PCR, an external
forward primer targeted to a 50 upstream canonical exonic sequence is
used with a reverse primer targeted to the predicted exon in question.
A 1:100 dilution of this ﬁrst round reaction is then used as the template
for the second round of PCR. The second round PCR then uses an
internal forward primer targeted to an exonic region between the
external forward primer and the previously used reverse exon primer.
As an example, the novel C. elegans exon in gene ZK180.2 is shown
with the expected PCR product band sizes (261bp ﬁrst round PCR,
156bp second round PCR). The second round reaction was cloned and
sequenced for validation of the prediction (DNA ladder is labeled as  ).
Table 1. EST and experimentally validated PASE predictions in
C. elegans and human
C. elegans % validated Human % validated
RefSeq entries 21584 – 22615 –
Introns 118457 – 197864 –
Translatable exons 6008 13.1% 207176 6.2%
Conserved exons 815 38.1% 5160 22.8%
Scansite410bits exons 113 37.2% 5489 19.4%
Scansite46bits exons 823 30.8% 35190 13.7%
Conserved &
Scansite410bits exons
20 (18) 90.0% 109 (57) 52.3%
Conserved &
Scansite46bits exons
140 (107) 76.4% 804 (334) 41.5%
The number of validated predictions is in parentheses.
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In order to understand the relative importance of the three
ﬁlters used by PASE—donor and acceptor site pairs,
sequence conservation, Scansite score—we analyzed the
enrichment of our validated alternative exons (either
experimentally or from EST data) from the set of all
candidate exons at diﬀerent steps in our algorithm.
Because our algorithm does not use EST information to
make its prediction, this is a reasonable estimate of
the speciﬁcity of the algorithm. PASE scanned 118457
introns in 21584 genes. After applying the acceptor–donor
exon model, Bayesian classiﬁer and reading frame ﬁlter
PASE found 6008 translatable exon predictions for worm
(Table 1). Here,  13% of these exon predictions are
observed as splice variants in the EST data (Table 1).
After selecting exons that are conserved between
C. elegans and C. briggsae, 815 predictions remained, of
which, 38.1% were validated splice forms (Table 1). Thus,
a 3- to 4-fold enrichment in documented splice variants is
observed when predicted translatable exons are limited to
regions of highly conserved sequence. Next, we analyzed
the contribution of the intracellular signaling motifs
without using a conservation ﬁlter. When a 6-bit
(or 10-bit) scoring threshold was used, 823 (or 113) of
the 6008 exons met this criteria, 30.8% (or 37.2%) of
which were in the EST database or experimentally
validated. When the conservation ﬁlter and the 6-bit
threshold were combined, 140 exons passed the ﬁlter,
74 (52.8%) of which were validated by spliced-ESTs.
Together with the 33 novel validated exons, a total of 107
(76.4%) exons were validated. From this analysis, we
conclude that conservation and Scansite score are largely
independent ﬁlters, and while both contribute signiﬁcantly
to the speciﬁcity of the algorithm, conservation plays a
slightly larger role.
Prediction of alternatively splicedsignaling exons inhuman
We next sought to use PASE to ﬁnd novel signaling exons
in humans. We used PASE to scan 197684 human introns
from 22615 genes (Table 1) and predicted 804 AS exons
involved in signaling. Of these, 308 (38.5%) could be
found in the human spliced-ESTs library (Supplementary
Table C). The remaining 496 predictions are either
novel exons or false positives of our algorithm. We
ranked these predictions by Scansite bit score and selected
the top 384 predictions for experimental validation.
Experimental validationof novel human predictions
Since testing each of the 384 predictions individually
across each tissue would require a large number of
experiments, we decided to pool total RNA from
18 human tissues (Supplementary Table D). In order to
compensate for the increased dilution of already low
expressed splice forms, we performed a sensitive,
semi-nested RT-PCR approach speciﬁc to the predicted
alternative exons followed by agarose gel electrophoresis
(Figure 3). Bands of the predicted size were cloned and
sequenced. Of the top 384 predictions that were not in the
EST database, we found 26 (6.7%) with correctly
predicted 50 splice junctions that were validated using
this approach (Table 3). Overall, our algorithm achieved a
speciﬁcity of  41.5% (334/804) in human (Table 1).
Analysisof thecriteria used topredict exonsin human
We wanted to understand the role each ﬁlter played in
distinguishing novel exons from pseudo-exons, so we
calculated how each step of our algorithm enriched for
bona ﬁde exons. PASE scanned 197684 human introns
( 1075 MB) and applied the acceptor–donor exon model,
Bayesian classiﬁer and reading frame ﬁlter to produce
207176 predictions (Table 1). Six percent of these
predictions are supported by experimental evidence
(either present in the EST database or validated by our
RT-PCR experiments). We next applied the conservation
ﬁlter. Of the 207176 exons, only 5160 (2.4%) were
conserved across vertebrate species. Twenty-two percent
of these had experimental support, somewhat lower than
that observed in C. elegans. We also separately searched
the 207176 translatable exons for signaling motifs with
log-odds scores greater than 6 bits (or 10 bits) and found
that 35190 (or 5489) exon predictions had one or more
motifs that met or exceeded this score threshold (Table 1).
In this subset of predictions, the enrichment for matches
with expressed sequences was slightly lower than in
C. elegans with 13.7% (19.4% for 10 bits) of these high-
scoring exons matching already observed spliced-EST
patterns in human. When both species conservation and
high-scoring Scansite motif criteria are combined, there is
a signiﬁcant increase for the enrichment of expressed
sequences with 308 of 804 (38.5%) predictions matching
with spliced-ESTs, reﬂecting  2-fold increase in speciﬁ-
city. Thus, including the 26 experimentally validated
exons, the total speciﬁcity was  41.5%. The results are
similar to those observed in C. elegans: both the
conservation and Scansite ﬁlters contribute signiﬁcantly
to our speciﬁcity and these ﬁlters are largely independent.
Determining thesensitivity of thePASE algorithm
A test set was created using splicing event data from the
Alternative Splicing Database (ASD) (24) and a list of
experimentally veriﬁed phosphorylation sites in eukaryotic
proteins from PhosphoELM (25). A set of 3797 single
cassette exon splicing events were extracted from the ASD
database and used in a BLASTX comparison with the
PhosphoELM database. A total of 20 PhosphoELM sites
had 100% sequence identity matched with a single cassette
exon (Supplementary Table E). We then applied PASE
to the corresponding REFSEQ gene structures that lack
the signaling cassette exons. Fourteen of the exons were
correctly predicted on both acceptor and donor splice sites
as well as correctly identifying the phosphorylation site
(total sensitivity (TP/TPþFN)¼70%). Of the false
negatives, two cassette exons were correctly predicted,
but PASE missed the phosphorylation site. Three exons
had incorrect donor sites predicted, of which one had the
phosphorylation site predicted correctly. One exon in the
test set was not predicted as well as having a missed
phosphorylation site.
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If our validated alternative exons are functional (i.e. play a
role in signal transduction), then we expect to ﬁnd them
predominantly in genes involved in intracellular signaling.
On the other hand, if PASE is not ﬁnding functional
exons, we would expect our predictions to be randomly
distributed across all genes (after correcting for diﬀerences
in the amount of intronic sequence). Therefore, to
determine if PASE is ﬁnding functional exons, we used
a hypergeometric test to calculate P-values of the
enrichment of our predicted alternative exons to occur
in signal transduction genes labeled with term
GO:0007165 (See Methods section). The 26 novel
human exons discovered in this study mapped to 20 GO
annotated genes, and our set of 334 validated exons
(covered by ESTs or experimentally validated here)
mapped to 218 GO annotated genes. In both cases,
a signiﬁcant enrichment was observed (8 of 20 GO
annotated genes, P¼0.002, and 62 of 218 GO annotated
genes, P¼3e–6). These results support the conclusion that
we are enriching for functional exons. A similar analysis
was performed on all the 804 predictions, which mapped
to 504 GO annotated genes, 151 of which were
signal transduction genes. Interestingly, this complete
set of predictions also showed signiﬁcant enrichment
(P54e–12).
Differential tissue-specific splicing ofthe novel exons
in LRP1and ESR1
To determine if the inclusion and/or exclusion of the exons
occurred in a tissue-speciﬁc manner, we performed
RT-PCR in each of the 18 human tissues. We focused
on two novel exons from two genes, estrogen receptor
alpha (ESR1/ERa) and low-density lipoprotein receptor 1
(LRP1), because both genes are involved in important
signal transduction pathways with clinical signiﬁcance
(26,27). We used ﬂanking exon primers for the canonical
splice junction and semi-nested, exon-speciﬁc primers
for the novel exon variant. In the case of ERa, we found
only breast and liver expressed the novel minor splice
variant, but all tissues tested expressed the constitutive
splice junction (Figure 4A). This result shows that the
novel ERa exon is typically excluded from most tissues,
and that its inclusion may be due to tissue-speciﬁc splicing
mechanisms. In the case of LRP1, we saw a broader
distribution of this minor splice variant, with the
exception of uterus tissue, which did not show any
expression of this novel exon (Figure 4B). The observation
that these isoforms are expressed in a tissue-speciﬁc
fashion lends further support to the idea that these are
not stochastic events, but instead regulated to perform a
tissue-speciﬁc function. Also, these results indicate that
the ﬂanking PCR is not sensitive for the detection of
these minor splice variants, compared to the exon-speciﬁc
semi-nested PCR approach.
DISCUSSION
Our algorithm is the ﬁrst attempt to predict signaling
cassette exons by combining sequence-based exon
prediction with additional information from short peptide
motifs that are bound or phosphorylated by signaling
proteins. This approach, when applied to C. elegans, made
140 predictions, 74 of which were present in the C. elegans
EST database. We experimentally tested the remaining
66 predictions, ﬁnding an additional 33 novel isoforms.
Table 3. Twenty-six novel human exons with predicted interaction sites conﬁrmed by cloning and sequencing
Gene symbol Gene description Intron Best Scansite HIT Score Motif
KCNH1 Potassium voltage-gated channel, subfamily H, 7 p85_SH2 13.1167 WEEDPYEYIRMKFDV
VPS8 Vacuolar protein sorting-associated 8 4 p85_SH2 11.891 WEPPVEDYISMTFSE
CRYGN Gamma N-crystallin variant 3 Abl_SH2 10.5251 GDGAWVLYEEPNYHG
CD58 Lymphocyte function-associated antigen 3 precursor (Ag3) 3 PKC_common 10.1748 GKNVTVKTIKKKQKR
PLEKHA6 Phosphoinositol 3-phosphate-binding protein-3 7 Cdc2_Kin 9.7482 FPYNYPPSPTVHDKM
ANKS1A/ODIN Ankyrin repeat and sterile alpha motif domain 4 PDGFR_Kin 9.3912 KYGPFDPYINAKNND
PLEKHA6 Phosphoinositol 3-phosphate-binding protein-3 13 PLCg_SH3 8.8428 ESPPAVPPLPSESRF
ESR1 Estrogen receptor 1 / estrogen receptor alpha 2 p85_SH3_m2 8.5929 EKPWQQMPLKGHNDY
ITGA6 Integrin alpha chain, alpha 6 5 Akt_Kin 8.5524 PPREQPDTFPDVMMN
MGC26733 Hypothetical protein MGC26733 18 Nck_2nd_SH3 8.5351 KVFDECFPDQPQIGH
SNX1 Sorting nexin 1 isoform c 11 PLCg_NSH2 8.4544 RYGQSGNYMELAWHC
MTMR6 Myotubularin-related protein 6 6 PKA_Kin 8.353 RPKRRMQSWWATQKD
RGPD5 RANBP2-like and GRIP domain containing 5 isoform 20 GSK3_Kin 8.0857 FWTSTPSSQPESKEP
LRP1 Low density lipoprotein-related receptor 1 19 Casn_Kin1 7.6201 GDGSDEQTCPEPADN
UTY Tetratricopeptide repeat protein isoform 1 12 Abl_SH3 7.3266 IEEAWSLPIPAELTS
PMS1 Postmeiotic segregation 1 4 PDGFR_Kin 7.2751 YMKKSGDYVTVVEDV
CREB5 cAMP responsive element binding protein 5 3 M1433 6.7301 MDFSKGHTWTIVMNA
RECQL5 RecQ protein-like 5 isoform 1 6 Crk_SH3 6.5986 ISTFQSPPPLPSRTL
PAK3 p21-activated kinase 3 2 GSK3_Kin 6.5144 FQTSRPVTVASSQSE
GTDC1 Glycosyltransferase-like domain containing 1 8 Nck_2nd_SH3 6.3065 LQEKEREPKMQFNTQ
LSAMP Limbic system-associated membrane protein 1 PKC_common 6.1958 FKQRKKPTLCRCVVE
PPP2R1B Protein phosphatase 2, regulatory subunit A (PR 65), beta 15 p38_Kin 6.1829 AAVRDIQSPCRAQGP
WDFY3 WD repeat and FYVE domain containing 3 isoform 2 Erk1_Kin 6.8017 EKQCALLSPKDFKAT
RPS6KC1 Ribosomal protein S6 kinase, 52kDa, polypeptide 1 p38_Kin 6.619 PGWWVIT S PNILANQ
OSR1/OXSR1 Oxidative-stress responsive 1 3 GSK3_Kin 6.5846 MVGSFANTNHLSRWW
RUNX3 Runt-related transcription factor 3 3 p38_Kin 6.2715 SCSCWLPSPHTDFFQ
Nucleic Acids Research, 2007, Vol. 35,No. 10 3199Thus, the overall speciﬁcity of our algorithm is  76.4%
(107/140) in C. elegans. We also used the algorithm to ﬁnd
human cassette exons, making 804 predictions, of which
308 were found as alternative exons in sequenced ESTs.
We experimentally tested 384 of the remaining 496
predictions and discovered an additional 26 novel
human exons (total speciﬁcity 334/804 41.5%). Overall,
we discovered 59 novel cassette exons. The human exons
that we uncovered are likely to be involved in signal
transduction because they were found in the introns of
known signal transduction genes more often than expected
by chance (P50.003). Using a test set of known
AS phosphorylation sites, we determined that the sensi-
tivity of our algorithm is  70%.
In both organisms analyzed, a large fraction of
predictions were found in the EST database—52.8% in
C. elegans and 38.5% in humans. Surprisingly, when we
experimentally tested the remaining predictions, we
saw diﬀerent discovery rates in the two organisms. In
C. elegans, 50% of the predicted exons not present in
spliced-ESTs were validated; in human, only 6.7% were
validated. Why was the discovery rate lower in humans
than C. elegans? One might hypothesize that because
C. elegans has shorter introns than humans ( 15-fold) and
their splice sites have a higher information content (28),
PASE makes more accurate predictions in C. elegans.
However, this seems unlikely to be the main reason
because the fraction of predictions covered by ESTs was
similar in C. elegans and humans. Another possibility is
that our experimental approach is not able to detect novel
exons in humans as well as it can in C. elegans. To validate
our C. elegans predictions, we used total RNA obtained
from whole worms at various stages of their life cycles.
This means that RNA from every cell type was present in
the sample, which may explain the higher discovery rate.
On the other hand, because we analyzed RNA from
18 human tissues, we sampled only a small fraction of
human cell types (out of a total possible 210 cell types).
Therefore, it is possible that some of our predictions were
bona ﬁde exons but were not present in our RNA pool,
and that our total speciﬁcity is at least 41.5%. In fact, the
GO term analysis for all 804 predictions (P54e–12)
suggests there may be more signaling exons that we have
yet to ﬁnd.
The novel exons found here all encode for phosphor-
ylation or binding sites; this allows one to predict
interactions with speciﬁc signaling proteins. For
example, the novel exon we found in estrogen receptor
alpha (ERa) is predicted to have a SH3 class II binding
site (K-P-X-X-Q/K-X) targeted by the p85a SH3 domain.
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Figure 4. Novel exons in ERa and LRP1 exhibit tissue-speciﬁc expression. Flanking exon primers were used in RT-PCR tests for expression of the
constitutive splice junctions, while exon-speciﬁc semi-nested primers were used to test for the expression of the novel alternative exon. (A) Expression
of the ERa constitutive exon 2–3 splice junction and the novel alternative exon across 18 tissues. The constitutive splice junction is expressed
in several tissues, shown as a 234bp PCR product. The novel exon is shown as a 244bp PCR product that is exclusively included in breast and liver.
(B) Expression of the LRP1 constitutive exon 18–19 splice junction and the novel alternative exon across 18 tissues. The constitutive splice junction is
expressed in most tissues, showing a 240bp PCR product. The novel exon is shown as a 128bp PCR product that is observed in all tissues except
uterus. Abbreviations for lanes: DNA ladder ( ), prostate (Pro), breast (Brt), colon (Col), skin (Ski), stomach (Stm), thymus (Thy), lung (Lun),
trachea (Tra), placenta (Pla), no template negative control ( N), and pooled tissue control (þP), brain (Brn), retina (Ret), skeletal Muscle (SM),
testis (Tes), kidney (Kid), ovary (Ovy), pancreas (Pan), uterus (Utr) and liver (Liv).   Lanes have size markers spaced at 50-nt intervals up to 350nt,
then the top two bands are for 500 and 766nt. The strong band corresponds to 200nt.
3200 Nucleic Acids Research, 2007, Vol. 35, No. 10Thus, one would predict that this isoform of ERa interacts
with a protein containing a p85a SH3 domain. Indeed,
previous work suggests that ERa directly interacts with
the p85a SH3 domain of PI3K, but since the canonical
ERa protein does not contain a binding site, the
mechanism of this interaction is currently unknown (29).
The cassette exon found here may explain this interaction.
The involvement of the estrogen-signaling pathway
in cancer (27), obesity (30,31) and cardiovascular disease
(32) makes this a particularly interesting direction for
future work. In addition, several other interesting exon
predictions coincided with published literature and
could be candidates for further investigation (See
Supplementary Table C).
Our exon validation approach was designed to facilitate
the detection of rare alternative exons in pooled RNA
samples, and we found it to be robust and sensitive.
One drawback to our validation pipeline was that only the
50 splice junctions were sequenced—the 30 splice junctions
were not. The correct 50 junction guarantees the preserva-
tion of the reading frame through the novel exon and the
presence of the putative interaction site, but the protein
might be modiﬁed or truncated downstream of the exon.
Therefore, for a subset of our predictions, we also
conﬁrmed the 30 splice junctions and found 31 out of
31 of them had the correct predicted 30 splice junction
(See Supplementary Data C and D).
The results presented here demonstrate that PASE is
able to ﬁnd alternative signaling exons with high
selectivity. We used PASE to predict exons in humans
and C. elegans and discovered 59 novel exons, several of
which may play important biological roles. Because PASE
does not use EST data to predict exons, it may be
particularly useful when applied to organisms with low
EST coverage (e.g. as was the case with C. elegans).
Currently, PASE is able to predict alternative single
cassette exons—we plan to extend the algorithm
to encompass exon extensions, intron retentions and
alternative 30 or 50 exons and possibly include the
prediction of the disruption of putative signaling motifs
(33). In addition, we anticipate an improvement in
performance when more signaling-related protein
features such as sites for acetylation, proteolysis and
even protein domains are included in these splicing event
predictions.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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